Lakefront Biotherapeutics NV (formerly Galapagos NV; Euronext & NASDAQ: LKFT) is a biotechnology company building a clinical-stage portfolio in immunology and inflammation.
The portfolio is anchored by gamgertamig, a BCMAxCD3 T-cell engager being developed for autoimmune diseases. Ongoing Phase 1b studies cover autoimmune cytopenias (ITP and AIHA) and seropositive autoimmune diseases (myositis, Sjögren's disease and pemphigus). Gamgertamig holds FDA Fast Track and Orphan Drug designations and is expected to enter registrational studies in 2027. Partner Keymed runs gamgertamig studies in Greater China.
The company also holds three preclinical autoimmune and inflammatory programs acquired with Ouro Medicines. Gilead holds an opt-in on these programs for a 50/50 profit split.
Current revenue consists mainly of supplying Jyseleca to Alfasigma under a transition agreement, plus limited collaboration revenue from Gilead.
The company is completing the wind-down of its CAR-T cell therapy activities. It sold its next-generation early-stage cell therapy pipeline to Armed Cell Therapeutics and discontinued GLPG3667.
With roughly €2.2 billion in cash and financial investments, Lakefront pursues a business-development model of acquiring and advancing high-quality assets. It also returns capital through share repurchases. The company plans to move its reporting and functional currency to the U.S. dollar. Updated
Tuesday's top analyst upgrades and downgrades included Advance Auto Parts, Dish Network, Intuit, Kroger, Palo Alto Networks, Qorvo, Starbucks and Texas Instruments.
Galapagos was crushed on Wednesday after the firm, in conjunction with Gilead, announced a new commercialization and development agreement for their Rheumatoid Arthritis (RA) treatment.
Monday's top analyst upgrades, downgrades and initiations included Agilent Technologies, Antero Midstream, Chewy, Domino's Pizza, eHealth, First Solar, Kraft Heinz, Newmont, Square, Tilray and Wayfair.
Thursday's top analyst upgrades, downgrades and initiations included Advanced Micro Devices, American Electric Power, Analog Devices, CenturyLink, Dish Network, Herbalife, NextEra Energy, NRG Energy, On Semiconductor and SolarEdge Technologies.
Monday's top analyst upgrades, downgrades and initiations included Alphabet, Apple, Bank of America, Citigroup, Dollar Tree, Nordstrom, Salesforce, Travelers and JD.com.
Lakefront Biotherapeutics NV (formerly Galapagos NV; Euronext & NASDAQ: LKFT) is a biotechnology company building a clinical-stage portfolio in immunology and inflammation. The portfolio is anchored by gamgertamig, a BCMAxCD3 T-cell engager being developed for autoimmune diseases.